News & Media
TheraCell Announces Immediate Release Of Its TheraFuze DBF® Fiber Bag Solution For Graft Containment In Spinal Surgery
TheraCell, Inc. a leading allograft solution company, today announced that its newest procedure-specific fiber graft form, the TheraFuze DBF Fiber Bag, is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures. Additionally, the company announced that a patent (U.S. Patent Number 10,639,157) related to the Fiber Bag was issued by the United States Patent and Trademark Office in May 2020.
TheraCell Announces Royalty Milestone From Licensing
TheraCell, Inc. a leading allograft solution company, today announced that as of September 30, 2020 its royalty income from the licensees of its base demineralized bone fiber technology had surpassed a $1.0M annual run rate. With consistent quarter over quarter growth, this achievement represents a 55% increase over the annual run rate observed at the same time last year.
TheraCell Announces First Surgical Use Of TheraFuze DBF® Fiber Anchor™ For Pedicle Screw Augmentation
TheraCell, Inc. a leading bone technology company today announced that it has completed the first three spine surgical cases using the world's first ever demineralized bone fiber screw anchor. This unique product acts much like a drywall anchor that provides immediate improvement in screw fixation in primary and revision cases.
TheraCell Announces Delivery of Over 12,000 Of Its Licensed Bone Grafts
TheraCell, Inc. a leading bone solution company today announced that over 12,000 of its novel demineralized bone fiber products have been delivered - primarily for use in spinal fusions. With steady double-digit quarter over quarter growth generated by its licensees and OEM partners, its products have reached an annual end customer sales rate of over $15M.
Our Partners
TheraCell’s 2nd Generation TheraFuze DBF® portfolio of demineralized bone fiber solutions includes the broadest range of demineralized bone fiber solutions available today - manufactured exclusively for TheraCell by Pinnacle Tissue Transplant, Phoenix, AZ.
Additionally, TheraCell has partnerships with AlloSource, Nuvasive and Australian Biotechnologies who sell products utilizing TheraCell technology under license.
Partnerships
TheraCell believes strongly in the power of partnerships to progress science and product development and seeks mutually rewarding partnerships. We currently have non exclusive partnerships with companies who are evaluating the synergy between TheraCell’s DBF™ fibers and growth factors and autologous cell therapy products.
TheraCell spun off two entities. In 2017 DermOQ Inc. was spun off with certain rights to TheraCell technologies in the field of dermatology. In 2019 Tetrous, Inc. was spun off with certain rights to TheraCell technologies in the fields of wound care and sports medicine.
Contact us to discuss partnering your technology, or any other partnership opportunities.
About Tetrous
Tetrous, Inc. is a regenerative medicine company which is guided by a team of influential surgeons, and regenerative medicine scientists, and led by experienced Medical Device executives. Tetrous has developed the next generation of advanced technologies for tissue repair in sports medicine and wound care. Tetrous has three synergistic technology platforms. The first of these is a proprietary and patented process for making demineralized bone fibers (TheraFuze DBF®) under license from TheraCell. The second platform is a patented process for creating procedure specific implants for rotator cuff repair and other sports medicine procedures as well as wound care. The third technology platform is a range of proprietary and patented oxygenation technologies under license from TheraCell. Oxygenation leads to improved tissue regeneration. Tetrous has licensed methodologies and gained patent protection for applying the oxygenation technology to bone and wound products. Founded in 2019 as a spinoff from TheraCell, Inc., the firm is headquartered in Los Angeles and maintains offices, laboratories and production facilities in the Boston area.
TheraCell DBF®, DBF™ and TheraCell™ are trademarks of TheraCell, Inc.
About DermOQ
DermOQ, Inc. is a skincare brand that brings the latest advances in oxygenated skincare from the world-renowned scientists who are revolutionizing tissue repair with oxygen. DermOQ, Inc. has developed a proprietary MaxOx™ oxygen delivery system for supplying molecular oxygen and other active nutrients into the skin to keep it in its most dynamic and alive state. Our patent pending innovative oxygen delivery systems use highly soluble oxygen compounds enhanced with molecular oxygen to penetrate and replenish the skin, delaying and reversing the effects of aging. Founded in 2017 as a spinoff from TheraCell, the brand is headquartered in Los Angeles and maintains offices, laboratories and production facilities in the Boston area. www.dermoq.com.
MaxOx™ is a trademark of DermOQ, Inc.